Dr Stuart Bloom

Dr Stuart BloomTel: 020 3447 9126
Fax: 020 3447 9217
Email: stuart.bloom@nhs.net

University College Hospital

Colorectal service, Endoscopy Unit, Gastrointestinal services

Professional background

Stuart Bloom has been a consultant gastroenterologist at UCLH since 1996. Stuart studied medicine at Oxford and St Thomas’s and trained in general Medicine and gastroenterology in Oxford and Liverpool. He was an MRC training fellow at the Institute of Molecular Medicine, Oxford, and was awarded his doctorate for work on adhesion molecules in the gastrointestinal tract. He was clinical director of gastroenterology at UCLH from 2001-2006 and was chair of the inflammatory bowel disease section of the British Society of Gastroenterology from 2006 to 2009. He was chair of the consultants committee at UCLH from 2008 - 2010. In March 2008 he was appointed GI specialty lead for the central and east London comprehensive research network and from 2008-2013 he was national GI specialty lead to the UK clinical research network. He is currently chair of the UK IBD Registry His key interests are research into gut inflammation, the clinical care of patients with inflammatory bowel disease and irritable bowel syndrome, teaching undergraduate and postgraduate students and in progressing electronic health records.

Research interests

  • General gastroenteorlogy
  • Inflammatory bowel disease (Crohns and colitis)
  • Irritable bowel syndrome
  • Endoscopy and bowel cancer screening


Briskin M, Winsor-Hynes D, Shyjan A, Bloom S, Wilson J, McEvoy L, Butcher EC, Kassam N, Mackay CR, Newman W, Ringler DJ.  Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. American Journal of Pathology 1997;151(1):97-110.

Harbord M, Hankin A, Bloom S, Mitchison H. Association between p47phox pseudogenes and inflammatory bowel disease. Blood 2003;101:3337

Basset C, Holton J, Bazeos A, Vaira D, Bloom S. Are Helicobacter species and enterotoxigenic Bacteroides fragilis involved in inflammatory bowel disease? Digestive Diseases and Sciences 2004;49(9):1425-32

Bloom S, Kiilerich S, Lassen MR, Forbes A, Leiper K, Langholz E, Irvine EJ, O’Morain C, Lowson D, Orm S. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Alimentary Pharmacology & Therapeutics 2004;19(8):871-878

Dhar A, Johnson KS, Novelli MR, Bown SG, Bigio IJ, Lovat LB, Bloom SL. Elastic scattering spectroscopy for the diagnosis of colonic lesions: initial results of a novel optical biopsy technique.
Gastrointestinal Endoscopy 2006;63:257-61

Marks DJB, Harbord MWN, MacAllister R, Rahman FZ, Young J, Al-Lazikani B, Lees W, Novelli M, Bloom S, Segal AW. Defective acute inflammation in Crohn’s disease: a clinical investigation. Lancet 2006;367:668678

Harbord MWN, Marks DJB, Forbes A, Bloom SL, Day RM, Segal AW. Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor. Alimentary Pharmacology & Therapeutics 2006;24:651660

Marks DJB, Rahman FZ, Novelli M, Yu RC, McCartney S, Bloom S, Segal AW. An exuberant inflammatory response to E coli: implications for the pathogenesis of ulcerative colitis and pyoderma gangrenosum. Gut 2006;55:1662-1663


Rahman FZ, Marks DJ, Hayee BH, Smith AM, Bloom SL, Segal AW. Phagocyte dysfunction and inflammatory bowel disease. Inflammatory Bowel Disease 2008 Apr 17 [Epub ahead of print]


GMC/GDC number: 2925871